within Pharmacolibrary.Drugs.N_NervousSystem.N02C_AntimigrainePreparations.N02CX01_Pizotifen;

model Pizotifen
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.78,
    Cl = 1.866666666666667e-05,
    adminDuration = 600,
    adminMass = 1.5 / 1000000,
    adminCount = 1,
    Vd = 0.019,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0025,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Pizotifen</td></tr><tr><td>ATC code:</td><td>N02CX01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>1.5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>19</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.96</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Pizotifen is a serotonin antagonist with antihistaminic and anticholinergic properties, primarily used as a prophylactic agent for the prevention of migraine and cluster headaches. It is approved for medical use in several countries, though less commonly used today due to the availability of newer migraine therapies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for pizotifen in healthy adult volunteers following oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N02CX01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Pizotifen;
